iA Global Asset Management Inc. Buys 2,006 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

iA Global Asset Management Inc. lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,026 shares of the medical equipment provider’s stock after acquiring an additional 2,006 shares during the period. iA Global Asset Management Inc.’s holdings in Zimmer Biomet were worth $1,376,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet in the 4th quarter worth $473,000. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares in the last quarter. M&T Bank Corp raised its position in shares of Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after acquiring an additional 8,709 shares in the last quarter. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet in the 4th quarter worth $7,825,000. Finally, Peddock Capital Advisors LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $654,000. 88.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Truist Financial reaffirmed a “hold” rating and set a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Raymond James reduced their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reduced their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Down 0.9 %

Shares of ZBH opened at $110.79 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $22.05 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.95 and a beta of 1.04. The stock’s 50-day moving average price is $106.74 and its 200-day moving average price is $106.93.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business earned $2.20 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.